Literature DB >> 8482368

Identification of mitogen-activated protein kinase phosphorylation sequences in mammalian h-Caldesmon.

L P Adam1, D R Hathaway.   

Abstract

h-Caldesmon in vascular smooth muscle is phosphorylated in response to pharmacologic stimulation. Although many kinases phosphorylate h-caldesmon, in vitro, the responsible kinase in intact tissue is unknown. The sites of phosphorylation in caldesmon from intact canine aortas have recently been identified and are consensus sequences for a proline-directed protein kinase. In this study, we investigated the phosphorylation of h-caldesmon by mitogen-activated protein kinase (MAPK). Purified, recombinant MAPK phosphorylated porcine stomach h-caldesmon to a stoichiometry approaching 2 mol phosphate/mol protein. Phosphorylated h-caldesmon was subjected to proteolysis and the phosphopeptides were purified by high performance liquid chromatography. Two major phosphopeptides were identified and sequenced. These two peptides, VTS*PTKV and S*PAPK, were identical to the sequences of the sites phosphorylated in intact tissue. Antibodies to several enzymes implicated in the cascade of activation of MAPK were used to evaluate vascular smooth muscle by Western blotting. All components were found to be present. These data suggest that MAPK can function as a 'caldesmon kinase' in vascular smooth muscle.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8482368     DOI: 10.1016/0014-5793(93)81110-l

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  24 in total

Review 1.  Protein kinase C isoenzymes: a review of their structure, regulation and role in regulating airways smooth muscle tone and mitogenesis.

Authors:  B L Webb; S J Hirst; M A Giembycz
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

2.  Mutant Caldesmon lacking cdc2 phosphorylation sites delays M-phase entry and inhibits cytokinesis.

Authors:  S Yamashiro; H Chern; Y Yamakita; F Matsumura
Journal:  Mol Biol Cell       Date:  2001-01       Impact factor: 4.138

3.  Simultaneous measurement of ERK, p38, and JNK MAP kinase cascades in vascular smooth muscle cells.

Authors:  D Chevalier; E Thorin; B G Allen
Journal:  J Pharmacol Toxicol Methods       Date:  2000 Sep-Oct       Impact factor: 1.950

4.  Regulation of mitogen-activated protein kinase by protein kinase C and mitogen-activated protein kinase phosphatase-1 in vascular smooth muscle.

Authors:  Danielle M Trappanese; Sarah Sivilich; Hillevi K Ets; Farah Kako; Michael V Autieri; Robert S Moreland
Journal:  Am J Physiol Cell Physiol       Date:  2016-04-06       Impact factor: 4.249

5.  A structural basis for substrate specificities of protein Ser/Thr kinases: primary sequence preference of casein kinases I and II, NIMA, phosphorylase kinase, calmodulin-dependent kinase II, CDK5, and Erk1.

Authors:  Z Songyang; K P Lu; Y T Kwon; L H Tsai; O Filhol; C Cochet; D A Brickey; T R Soderling; C Bartleson; D J Graves; A J DeMaggio; M F Hoekstra; J Blenis; T Hunter; L C Cantley
Journal:  Mol Cell Biol       Date:  1996-11       Impact factor: 4.272

6.  Listeria monocytogenes invasion of epithelial cells requires the MEK-1/ERK-2 mitogen-activated protein kinase pathway.

Authors:  P Tang; C L Sutherland; M R Gold; B B Finlay
Journal:  Infect Immun       Date:  1998-03       Impact factor: 3.441

7.  Activation of MAP kinases and phosphorylation of caldesmon in canine colonic smooth muscle.

Authors:  W T Gerthoffer; I A Yamboliev; M Shearer; J Pohl; R Haynes; S Dang; K Sato; J R Sellers
Journal:  J Physiol       Date:  1996-09-15       Impact factor: 5.182

8.  Phosphorylation of caldesmon by smooth-muscle casein kinase II.

Authors:  C Sutherland; B S Renaux; D J McKay; M P Walsh
Journal:  J Muscle Res Cell Motil       Date:  1994-08       Impact factor: 2.698

Review 9.  Caldesmon as a therapeutic target for proliferative vascular diseases.

Authors:  Chi-Ming Hai
Journal:  Mini Rev Med Chem       Date:  2008-10       Impact factor: 3.862

Review 10.  Smooth muscle signalling pathways in health and disease.

Authors:  H R Kim; S Appel; S Vetterkind; S S Gangopadhyay; K G Morgan
Journal:  J Cell Mol Med       Date:  2008-12       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.